The $7.2M cash balance at current burn rate provides less than 2 quarters of runway. The explicit 'evaluating capital alternatives' language in the filing is a near-certain precursor to a dilutive offering (S-3 shelf or private placement). Traders should anticipate significant share dilution and price pressure. The government engagement narrative (BARDA, NIAID) is a long-term catalyst but does not offset the immediate financing overhang.
Price Chart
Executive Summary
Valion Bio (VBIO) reported Q1 2026 results, its first full quarter post-transformation from Tivic Health. Net loss widened to $6.2M from $1.5M YoY, driven by inclusion of Velocity Bioworks costs and pipeline advancement. Cash burn is rapid — cash dropped from $12.6M to $7.2M in three months — and the company explicitly flagged it is evaluating capital alternatives, signaling a likely dilutive offering ahead.
Key Financial Metrics
Key Facts
- Net loss of $6.2M vs $1.5M YoY, driven by $5.6M in operating expenses (up 4x from $1.4M)
- Cash and cash equivalents fell to $7.2M from $12.6M at Dec 31, 2025 — a $5.4M quarterly burn
- Company states it 'continues to evaluate capital alternatives' — strong signal of imminent dilution
- No revenue reported; pre-revenue clinical-stage biotech with no near-term commercialization path
- Weighted-average shares outstanding surged to 2,883,650 from 569,368 YoY, reflecting massive dilution from prior financing
Financial Impact
Cash burn of $5.4M in the quarter; net loss of $6.2M; operating expenses $5.6M vs $1.4M YoY
Risk Factors
- Imminent dilutive capital raise likely within 1-2 quarters given $7.2M cash and $5.4M quarterly burn
- No revenue and no near-term commercialization path for Entolimod (Animal Rule approval timeline uncertain)
- Massive share count increase (5x YoY) signals ongoing dilution trend
- Nasdaq listing compliance risk given $3M market cap and potential for continued low share price
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-017082 |
| Document: tivc20260405_8k.htm | 0001437749-26-017082 |
| Document: 0001437749-26-017082-index-headers.html | 0001437749-26-017082 |
| Document: 0001437749-26-017082-index.html | 0001437749-26-017082 |
| Document: 0001437749-26-017082.txt | 0001437749-26-017082 |
| 8-K Data (Synthetic) | 0001437749-26-017082 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.8253 (+7.79%) |
Oct 26, 2026 1d ago | 8-K | $1.15 | awaiting T+20 | — | $0.8253 (−27.98%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.8253 (−13.67%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8253 (+26.31%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8253 (+26.31%) |
Oct 16, 2026 10d ago | S-3 | $1.16 | awaiting T+20 | — | $0.8253 (+28.85%) |
Oct 16, 2026 10d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.8253 (+28.85%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.8253 (−32.90%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.8253 (−43.08%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.8253 (+62.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers